Nektar Therapeutics's total inventories for the quarter that ended in Dec. 2023 was $16.10 Mil. Nektar Therapeutics's average total inventories from the quarter that ended in Sep. 2023 to the quarter that ended in Dec. 2023 was $15.62 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Nektar Therapeutics's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $0.24.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Nektar Therapeutics's Days Inventory for the
three
months ended in Dec. 2023 was 195.65.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Nektar Therapeutics's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.47.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Nektar Therapeutics's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.65.
Nektar Therapeutics Total Inventories Historical Data
The historical data trend for Nektar Therapeutics's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Nektar Therapeutics (NAS:NKTR) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Nektar Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Nektar Therapeutics's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Nektar Therapeutics Total Inventories Related Terms
Thank you for viewing the detailed overview of Nektar Therapeutics's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.
Nektar Therapeutics (Nektar Therapeutics) Business Description
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, the company is focused on activating the immune system's natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NKTR has been successfully added to your 